ecancer

ESMO 2022: Renal roundup

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

12 Sep 2022

Emerging systemic therapies in rare urothelial cancer variants

Dr Bradley McGregor - Dana-Farber Cancer Institute, Boston, USA

12 Sep 2022

Lenvatinib plus pembro for aRCC - update on the CLEAR study

Dr Bradley McGregor - Dana-Farber Cancer Institute, Boston, USA

12 Sep 2022

RADICALS-HD trial: androgen deprivation therapy with post-operative radiotherapy to treat prostate cancer

Prof Chris Parker - Institute of Cancer Research, Sutton, UK

12 Sep 2022

ESMO 2022: Latest in PARP inhibitors for metastatic prostate cancer

Dr Neal Shore, Dr Pasquale Rescigno, Prof Noel Clarke and Dr Friederike Schlürmann

11 Sep 2022

A new era of early cancer detection with blood test may change cancer screening paradigms

Dr Deb Schrag, Memorial Sloan Kettering Cancer Center, New York, USA

11 Sep 2022

New era of early cancer detection blood tests on the horizon

Dr Deborah Schrag - Memorial Sloan Kettering Cancer Center, New York City, USA

11 Sep 2022

Prognostic model of all-cause mortality at 30 days in patients with cancer and COVID-19

Dr Chris Labaki - Dana-Farber Cancer Institute, Boston, USA

11 Sep 2022

New data presented at ESMO for multi-cancer early detection

Dr Tom Beer - Vice President and Chief Medical Officer of Exact Sciences

10 Sep 2022

Bladder cancer: Current state and future directions in treatment

Prof Jorge Garcia - GU Medical Oncology Program, UH Seidman Cancer Center, Case Western Reserve University, Cleveland, USA

15 Aug 2022

Optimum treatment algorithm in management of advanced prostate cancer

Prof Jorge Garcia - GU Medical Oncology Program, UH Seidman Cancer Center, Case Western Reserve University, Cleveland, USA

15 Aug 2022

Working to improve global cancer care access in low middle-income countries

Dr Julie Gralow, Prof Eduardo Cazap

25 Jul 2022

More from ecancer